메뉴 건너뛰기




Volumn 145, Issue 3, 2014, Pages 579-585

Predicting pulmonary fibrosis disease course from past trends in pulmonary function

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREND STUDY;

EID: 84896767563     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0844     Document Type: Article
Times cited : (103)

References (28)
  • 1
    • 79952717349 scopus 로고    scopus 로고
    • ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis . An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management
    • Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management . Am J Respir Crit Care Med . 2011; 183 (6) : 788 - 824 .
    • (2011) Am J Respir Crit Care Med. , vol.183 , Issue.6 , pp. 788-824
    • Raghu, G.1    Collard, H.R.2    Egan, J.J.3
  • 2
    • 20944434994 scopus 로고    scopus 로고
    • Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
    • . Azuma A, Nukiwa T, Tsuboi E, et al . Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis . Am J Respir Crit Care Med . 2005; 171 (9) : 1040 - 1047 .
    • (2005) Am J Respir Crit Care Med , vol.171 , Issue.9 , pp. 1040-1047
    • Azuma, A.1    Nukiwa, T.2    Tsuboi, E.3
  • 3
    • 28144459814 scopus 로고    scopus 로고
    • Ifigenia study group . High-dose acetylcysteine in idiopathic pulmonary fibrosis
    • Demedts M, Behr J, Buhl R, et al; IFIGENIA Study Group . High-dose acetylcysteine in idiopathic pulmonary fibrosis . N Engl J Med . 2005; 353 (21) : 2229 - 2242
    • (2005) N Engl J Med. , vol.353 , Issue.21 , pp. 2229-2242
    • Demedts, M.1    Behr, J.2    Buhl, R.3
  • 4
    • 67650349068 scopus 로고    scopus 로고
    • Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (inspire): A multicentre,randomised, placebo-controlled trial
    • INSPIRE Study Group
    • King TE Jr, Albera C, Bradford WZ, et al ; INSPIRE Study Group . Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre,= randomised, placebo-controlled trial . Lancet . 2009; 374 (9685): 222 - 228 .
    • (2009) Lancet. , vol.374 , Issue.9685 , pp. 222-228
    • King, Jr.T.E.1    Albera, C.2    Bradford, W.Z.3
  • 5
    • 37849012578 scopus 로고    scopus 로고
    • BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis
    • . King TE Jr, Behr J, Brown KK, et al . BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis . Am J Respir Crit Care Med . 2008; 177 (1) : 75 - 81 .
    • (2008) Am J Respir Crit Care Med , vol.177 , Issue.1 , pp. 75-81
    • King, Jr.T.E.1    Behr, J.2    Brown, K.K.3
  • 6
    • 80051566676 scopus 로고    scopus 로고
    • BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis
    • . King TE Jr, Brown KK, Raghu G, et al . BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis . Am J Respir Crit Care Med . 2011; 184 (1) : 92 - 99 .
    • (2011) Am J Respir Crit Care Med , vol.184 , Issue.1 , pp. 92-99
    • King, Jr.T.E.1    Brown, K.K.2    Raghu, G.3
  • 7
    • 79956341531 scopus 로고    scopus 로고
    • Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials
    • CAPACITY Study Group
    • Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials . Lancet . 2011; 377 (9779) : 1760 - 1769 .
    • (2011) Lancet. , vol.377 , Issue.9779 , pp. 1760-1769
    • Noble, P.W.1    Albera, C.2    Bradford, W.Z.3
  • 8
    • 0345824715 scopus 로고    scopus 로고
    • A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
    • Idiopathic Pulmonary Fibrosis Study Group
    • Raghu G, Brown KK, Bradford WZ, et al; Idiopathic Pulmonary Fibrosis Study Group . A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis . N Engl J Med . 2004; 350 (2) : 125 - 133 .
    • (2004) N Engl J Med . , vol.350 , Issue.2 , pp. 125-133
    • Raghu, G.1    Brown, K.K.2    Bradford, W.Z.3
  • 9
    • 55549147184 scopus 로고    scopus 로고
    • Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebocontrolled trial
    • Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebocontrolled trial . Am J Respir Crit Care Med . 2008; 178 (9) :948 - 955 .
    • (2008) Am J Respir Crit Care Med , vol.178 , Issue.9 , pp. 948-955
    • Raghu, G.1    Brown, K.K.2    Costabel, U.3
  • 10
    • 0032926937 scopus 로고    scopus 로고
    • Treatment of idiopathic pulmonary fibrosis with a new antifi brotic agent, pirfenidone: Results of a prospective, open-label phase II study
    • Raghu G, Johnson WC, Lockhart D, Mageto Y . Treatment of idiopathic pulmonary fibrosis with a new antifi brotic agent, pirfenidone: results of a prospective, open-label phase II study . Am J Respir Crit Care Med . 1999; 159 (4 pt 1) : 1061 - 1069 .
    • (1999) Am J Respir Crit Care Med , vol.159 , Issue.4 PART 1 , pp. 1061-1069
    • Raghu, G.1    Johnson, W.C.2    Lockhart, D.3    Mageto, Y.4
  • 11
    • 77951160564 scopus 로고    scopus 로고
    • Pirfenidone in idiopathic pulmonary fibrosis
    • Taniguchi H, Ebina M, Kondoh Y, et al . Pirfenidone in idiopathic pulmonary fibrosis . Eur Respir J . 2010; 35 (4) : 821 - 829 .
    • (2010) Eur Respir J , vol.35 , Issue.4 , pp. 821-829
    • Taniguchi, H.1    Ebina, M.2    Kondoh, Y.3
  • 12
    • 77956640423 scopus 로고    scopus 로고
    • A controlled trial of sildenafi l in advanced idiopathic pulmonary fibrosis
    • Idiopathic Pulmonary Fibrosis Clinical Research Network
    • Idiopathic Pulmonary Fibrosis Clinical Research Network; Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafi l in advanced idiopathic pulmonary fibrosis . N Engl J Med . 2010; 363 (7) : 620 - 628 .
    • (2010) N Engl J Med . , vol.363 , Issue.7 , pp. 620-628
    • Zisman, D.A.1    Schwarz, M.2    Anstrom, K.J.3    Collard, H.R.4    Flaherty, K.R.5    Hunninghake, G.W.6
  • 13
    • 63349091740 scopus 로고    scopus 로고
    • The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis
    • . Fell CD, Liu LX, Motika C, et al . The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis . Am J Respir Crit Care Med . 2009; 179 (5) : 402 - 407 .
    • (2009) Am J Respir Crit Care Med , vol.179 , Issue.5 , pp. 402-407
    • Fell, C.D.1    Liu, L.X.2    Motika, C.3
  • 14
    • 0037312730 scopus 로고    scopus 로고
    • Radiological versus histological diagnosis in UIP and NSIP: Survival implications
    • . Flaherty KR, Thwaite EL, Kazerooni EA, et al . Radiological versus histological diagnosis in UIP and NSIP: survival implications . Thorax . 2003; 58 (2) : 143 - 148 .
    • (2003) Thorax , vol.58 , Issue.2 , pp. 143-148
    • Flaherty, K.R.1    Thwaite, E.L.2    Kazerooni, E.A.3
  • 15
    • 18244383070 scopus 로고    scopus 로고
    • Clinical signifi - Cance of histological classification of idiopathic interstitial pneumonia
    • . Flaherty KR, Toews GB, Travis WD, et al . Clinical signifi - cance of histological classification of idiopathic interstitial pneumonia . Eur Respir J . 2002; 19 (2) : 275 - 283 .
    • (2002) Eur Respir J , vol.19 , Issue.2 , pp. 275-283
    • Flaherty, K.R.1    Toews, G.B.2    Travis, W.D.3
  • 16
    • 13844316832 scopus 로고    scopus 로고
    • Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis
    • . King TE Jr, Safrin S, Starko KM, et al . Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis . Chest . 2005; 127 (1) : 171 - 177 .
    • (2005) Chest , vol.127 , Issue.1 , pp. 171-177
    • King, Jr.T.E.1    Safrin, S.2    Starko, K.M.3
  • 17
    • 10744229010 scopus 로고    scopus 로고
    • Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia
    • Lama VN, Flaherty KR, Toews GB, et al . Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia . Am J Respir Crit Care Med . 2003; 168 (9) : 1084 - 1090 .
    • (2003) Am J Respir Crit Care Med , vol.168 , Issue.9 , pp. 1084-1090
    • Lama, V.N.1    Flaherty, K.R.2    Toews, G.B.3
  • 19
    • 0041374153 scopus 로고    scopus 로고
    • Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia
    • Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia . Am J Respir Crit Care Med . 2003; 168 (5) : 543 - 548 .
    • (2003) Am J Respir Crit Care Med , vol.168 , Issue.5 , pp. 543-548
    • Flaherty, K.R.1    Mumford, J.A.2    Murray, S.3
  • 20
    • 0041374155 scopus 로고    scopus 로고
    • Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends
    • Latsi PI, du Bois RM, Nicholson AG, et al . Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends . Am J Respir Crit Care Med . 2003; 168 (5) : 531 - 537 .
    • (2003) Am J Respir Crit Care Med , vol.168 , Issue.5 , pp. 531-537
    • Latsi, P.I.1    Du Bois, R.M.2    Nicholson, A.G.3
  • 21
    • 20144381640 scopus 로고    scopus 로고
    • Physiology is a stronger predictor of survival than pathology in fi brotic interstitial pneumonia
    • Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fi brotic interstitial pneumonia . Am J Respir Crit Care Med . 2005; 171 (6) : 639 - 644 .
    • (2005) Am J Respir Crit Care Med , vol.171 , Issue.6 , pp. 639-644
    • Jegal, Y.1    Kim, D.S.2    Shim, T.S.3
  • 22
    • 80051819865 scopus 로고    scopus 로고
    • Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
    • du Bois RM, Weycker D, Albera C, et al . Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis . Am J Respir Crit Care Med . 2011; 184 (4) :459 - 466 .
    • (2011) Am J Respir Crit Care Med , vol.184 , Issue.4 , pp. 459-466
    • Du Bois, R.M.1    Weycker, D.2    Albera, C.3
  • 23
    • 84862826491 scopus 로고    scopus 로고
    • Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
    • Richeldi L, Ryerson CJ, Lee JS, et al . Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis . Thorax . 2012; 67 (5) : 407-411 .
    • (2012) Thorax , vol.67 , Issue.5 , pp. 407-411
    • Richeldi, L.1    Ryerson, C.J.2    Lee, J.S.3
  • 24
    • 0034011982 scopus 로고    scopus 로고
    • Idiopathic pulmonary fibrosis: Diagnosis and treatment
    • American Thoracic Society,International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)., American Thoracic Society.
    • American Thoracic Society . American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) . Am J Respir Crit Care Med . 2000; 161 (2 pt 1) : 646 - 664 .
    • (2000) Am J Respir Crit Care Med , vol.161 , Issue.2 PART 1 , pp. 646-664
  • 25
    • 84861382039 scopus 로고    scopus 로고
    • Idiopathic pulmonary fibrosis: Clinically meaningful primary endpoints in phase 3 clinical trials
    • Raghu G, Collard HR, Anstrom KJ, et al . Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials . Am J Respir Crit Care Med . 2012; 185 (10) :1044 - 1048 .
    • (2012) Am J Respir Crit Care Med , vol.185 , Issue.10 , pp. 1044-1048
    • Raghu, G.1    Collard, H.R.2    Anstrom, K.J.3
  • 26
    • 84865112235 scopus 로고    scopus 로고
    • Diopathic pulmonary fibrosis: Lung function is a clinically meaningful endpoint for phase III trials
    • du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW . diopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials . Am J Respir Crit Care Med . 2012; 186 (8) : 712 - 715 .
    • (2012) Am J Respir Crit Care Med , vol.186 , Issue.8 , pp. 712-715
    • Du Bois, R.M.1    Nathan, S.D.2    Richeldi, L.3    Schwarz, M.I.4    Noble, P.W.5
  • 27
    • 84455168726 scopus 로고    scopus 로고
    • Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference
    • du Bois RM, Weycker D, Albera C, et al . Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference . Am J Respir Crit Care Med . 2011; 184 (12) : 1382 - 1389 .
    • (2011) Am J Respir Crit Care Med , vol.184 , Issue.12 , pp. 1382-1389
    • Du Bois, R.M.1    Weycker, D.2    Albera, C.3
  • 28
    • 79955520497 scopus 로고    scopus 로고
    • Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference
    • du Bois RM, Weycker D, Albera C, et al . Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference . Am J Respir Crit Care Med . 2011; 183 (9) : 1231 - 1237 .
    • (2011) Am J Respir Crit Care Med , vol.183 , Issue.9 , pp. 1231-1237
    • Du Bois, R.M.1    Weycker, D.2    Albera, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.